NASDAQ
40.17USD
0.00 (0.00%)
We have scored 11 news catalysts on XOMA Royalty Corp. (XOMA) over the past 12 months. The biggest single-day move next to one of them came Jan 12, 2026, when XOMA closed −10.3%: “ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sun Country Airlines”. Coverage across the window leans negative (average ticker sentiment −0.31). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
503.8M
P/E
—
EPS
—
Beta
0.86
52W range
22.29-45.22
Day range
39.87–43.53
Open
43.53
Prev close
40.17
Volume
0
Avg volume
327.5K
Dividend
0.00
IPO
1986-06-06
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about XOMA Royalty Corp. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for XOMA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main office in Emeryville, California.
